Palvella Therapeutics IncPVLA
Price$132.73

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$61.7MTTM through 30 Jun 2026
Free Cash Flow -$36.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-28.4%ROE
-24.3%ROA

Balance Sheet Health

Current Ratio21.18x
Cash & Equivalents$187.8M

Quality Metrics

Altman Z-Score36.74
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'17'18'19'20'21'22'23
FY2023: $42.8M
Diluted EPS-$4.85TTM
'20'21'23'24'25
FY2025: $-3.71

Dividend

No dividend

Capital Allocation

R&D Spend$35.5M

Segment Performance

SegmentRevenueYoYOutlook
Rare Disease Biopharmaceuticals$00.0%
View details

NDA submission for microcystic lymphatic malformations is on track for the second half of 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.